Page 13 - Mylan EpiPen

In October 2016, Mylan announced a settlement with the

DOJ over rebates paid by Mylan to states under the

Medicaid Drug Rebate Program. Mylan agreed to pay a $465

million payment.

Also in October 2016, the Heather Bresch testified to a

congressional committee that Pfizer/King charged Mylan

about $34.50 for one device. Furthermore, Bresch said
Mylan’s profit was $100 for a two-pack of the injectors,

despite a $608 list price.

This $100 profit figure appeared to be questionable and a

few days later the company admitted that it had

substantially affected its calculation of EpiPen profits by

applying the statutory U.S. corporate tax rate of 37.5%- five